Astellas Pharma Europe B.V. clinical trials

A country office of Astellas Pharma Inc

The registry lists 125 studies whose lead sponsor is Astellas Pharma Europe B.V.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 125. List all 125 → · All Astellas Pharma Inc studies →

• Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)Not yet recruitingNCT07858500

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical PracticeRecruitingNCT07602530

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®CompletedNCT01294020Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During MenopauseCompletedNCT07455812

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide AloneCompletedNCT02288247Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or DeathCompletedNCT03619980

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate CancerCompletedNCT02116582Phase 4

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract SymptomsCompletedNCT01021332Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract SymptomsCompletedNCT01018511Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable DialysisCompletedNCT02278341Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedNCT02218372Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a TransplantCompletedNCT02118896Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyCompletedNCT02124668Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.CompletedNCT01638000Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study of ASP8302 in Participants With Underactive BladderCompletedNCT03702777Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly SubjectsCompletedNCT04742517Phase 1

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor OveractivityCompletedNCT01565694Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin AlfaCompletedNCT02021318Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring DialysisCompletedNCT01887600Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076CompletedNCT01655069Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on MetforminCompletedNCT02794792Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor OveractivityCompletedNCT02751931Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)CompletedNCT01613586Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ TransplantationCompletedNCT01371331Phase 4

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of TimeCompletedNCT01614665Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft RecipientsTerminatedNCT01371344Phase 4

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive BladderCompletedNCT01340027Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical PracticeCompletedNCT02320773

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive BladderCompletedNCT02045862Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)CompletedNCT02437591Phase 4

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the KneeCompletedNCT02611466Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older PopulationCompletedNCT02254967Phase 4

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney DiseaseCompletedNCT02358096Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on DialysisCompletedNCT04042350

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive BladderCompletedNCT01972841Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)CompletedNCT01908829Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial CystitisCompletedNCT03282318Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney TransplantCompletedNCT02057484

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney DiseaseCompletedNCT02218099Phase 1/2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant PatientsCompletedNCT02555787

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)CompletedNCT02302079Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) RegisterCompletedNCT05015998

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)CompletedNCT02526979Phase 1

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active DrugCompletedNCT01565707Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01604928Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)CompletedNCT01981954Phase 3

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• A Survey About Trade-offs When Choosing Menopause TreatmentsCompletedNCT05300568

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Survey About Hot Flashes in Women Going Through the MenopauseCompletedNCT05083884

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.

• A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic PainCompletedNCT01767090Phase 2

  Sponsor listed in the registry: Astellas Pharma Europe B.V.

• European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)CompletedNCT02495974

  Sponsor listed in the registry: Astellas Pharma Europe Ltd.